Navigation Links
Failure of Iclusig, Ariad’s Pharmaceutical Drug, No Surprise to CBCD
Date:10/20/2013

Rochester, NY (PRWEB) October 20, 2013

The failure of Ariad Pharmaceutical’s leukemia drug, Iclusig is no surprise to the CBCD. If top management at Ariad, and/or their investors, had turned to the CBCD, the Center would have told them that the chance of completing a successful clinical trial was almost zero.

What’s the argument? The productivity crisis in pharmaceutical R&D.

Iclusig was designed to target one specific molecule. However, like every drug, it impacts more than the specific molecule it was designed to target. When a drug impacts the ‘other’ molecules, it causes adverse reactions, or side effects. This was clearly the case in the development of Iclusig because in this case, some of the ‘other’ molecules were actually known.

As the author of an article published in February, 2013 in the formulary management journal P & T wrote, “The primary target (of Iclusig) is Bcr-Abl, an abnormal tyrosine kinase that is expressed in CML and Ph+ ALL (2).” If one carefully notes, however, the drug also “selectively blocks other tyrosine kinases, including FLT3, RET, KIT, and the members of the fibroblast growth factor receptor (FGFR) and platelet-derived growth factor (PDGFR) families (2).”

What kind of adverse reactions resulted from Iclusig’s impact on the ‘other’ molecules?

The answer is frightening. “Serious and fatal cases of arterial thrombosis (the formulation of a blood clot) and liver injury have occurred during treatment… cardiovascular, cerebrovascular, and peripheral vascular thrombosis, including fatal myocardial infarction (MI) (heart attack) and stroke have occurred in treated patients (2).”

In fact, because of these dangerous adverse reactions, “Ariad Pharmaceuticals Inc. abruptly terminated a pivotal clinical trial of its leukemia drug … a move that raised new safety questions and sent the company’s shares plunging more than 40 percent (1).”

Inclusig is
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related biology technology :

1. NIH media availability: Protein linked to increased risk of heart failure and death in older adults
2. Heart Failure Society of America Annual Meeting To Feature Several Satellite Symposia
3. A new treatment for kidney disease-associated heart failure?
4. Blocking digestive enzymes may reverse shock, stop multiorgan failure
5. Galectin-3 Assessed as a Biomarker of Heart Failure: Key Clinical Trial Findings Published by Dove Medical Press
6. At Three Months Post Launch, Two-Thirds of Surveyed U.S. Rheumatologists Believe that Initiations of Pfizers Xeljanz in the Rheumatoid Arthritis Treatment Algorithm Will Occur Following at Least Two Biologic Failures
7. SynCardia Total Artificial Heart Bridges Mother of Four with Congenital Heart Defect & Biventricular Heart Failure to Transplant
8. The Prevention of Heart Failure
9. Center Of Reproductive Medicine Participates In The Thrive-IVF Research Study To Help Improve Pregnancy Success Rates And Outcomes In Women With A History Of Repeated In Vitro Fertilization (IVF) Failures
10. Houston Fertility Institute Participates In The Thrive-IVF Research Study To Help Improve Pregnancy Success Rates And Outcomes In Women With A History Of Repeated In Vitro Fertilization (IVF) Failures
11. Celladon Corporation Announces Publication of Long Term Follow-Up Results from the MYDICAR CUPID 1 Trial in Advanced Heart Failure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... research platform uses a laser to measure ... stress and heating, an approach likely to ... and batteries., This new technique, called nanomechanical ... and the surface stress of microscale structures ... the merits of surface-stress influence on mechanical ...
(Date:8/28/2014)... The ability for organizations to attract ... allow individuals to perform at the highest of levels, ... looking to compete in this post–recession era. The ... as the sector increasingly focuses on the importance of ... have real results on the organization's development and the ...
(Date:8/28/2014)... August 28, 2014 Sterlitech is proud ... membranes to its stable of products . ... weight cut-offs and include membrane filters with surface charges. ... in customer demand for our membrane process testing equipment, ... of flat sheet membranes,” explains Sterlitech President Mark Spatz. ...
(Date:8/28/2014)... BELLINGHAM, Washington, USA (PRWEB) August 27, 2014 ... Colorado next month for SPIE Laser Damage 2014 ... on optical materials for high-power lasers will run 14-17 ... international society for optics and photonics . , The ... key for understanding laser damage to optical materials will ...
Breaking Biology Technology:New analytical technology reveals 'nanomechanical' surface traits 2New analytical technology reveals 'nanomechanical' surface traits 3Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 2Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 3Sterlitech Corporation Enhances Its Selection of Flat Sheet Membrane Filters 2Laser Damage to Draw Researchers, Engineers, Scientists to 46th Annual Conference 2Laser Damage to Draw Researchers, Engineers, Scientists to 46th Annual Conference 3
... Therapeutics, Inc. (Nasdaq: TSRX ) announced today that ... present "Innovative Antibacterial Drugs by Design; The Trius Therapeutics Story" ... October 26, 2010 from 5:30-9:30 p.m. PT. ... . About Trius Therapeutics ...
... Pa., Oct. 22 Encorium Group, Inc. (Nasdaq: ... research organization (CRO) conducting studies in over 30 ... and biotechnology companies, today announced that, on October ... Listing Qualifications Panel (the "Panel") has determined to ...
... in German . Jena (21 October ... improving a fabrication process for Atomic Force Microscopy (AFM) probe ... surfaces so that even tiniest nano structures become visible. Knowledge ... of new materials and carrier systems for active substances. The ...
Cached Biology Technology:Encorium Announces NASDAQ Panel Decision to Delist Common Stock; Announces Changes to its Board of Directors 2Encorium Announces NASDAQ Panel Decision to Delist Common Stock; Announces Changes to its Board of Directors 3Encorium Announces NASDAQ Panel Decision to Delist Common Stock; Announces Changes to its Board of Directors 4AFM tips from the microwave 2
(Date:8/29/2014)... cell,s nucleus, chromosomal DNA is tightly bound to ... call chromatin. Until about two decades ago, histones ... packing material around which the glamorous DNA strands ... greater appreciation for how DNA/histone interactions govern gene ... institutions studying the sequence of the genome from ...
(Date:8/29/2014)... of the Tibetan plateau -- the largest topographic anomaly ... both its profound effect on climate and its reflection ... GSA Bulletin , Katharine Huntington and colleagues employ a ... modern and fossil snail shells to investigate the uplift ... , Views range widely on the timing of surface ...
(Date:8/28/2014)... pleased to announce the selection of Dr. Fred Baxendale ... acknowledges those who have served ESA for at least ... the Society that has reached an extraordinary level. Candidates ... Board and then voted on by the ESA membership. ... at Entomology 2014, ESA,s Annual Meeting in Portland, Oregon ...
Breaking Biology News(10 mins):'K-to-M' histone mutations: How repressing the repressors may drive tissue-specific cancers 2'K-to-M' histone mutations: How repressing the repressors may drive tissue-specific cancers 3Snails tell of the rise and fall of the Tibetan Plateau 2Snails tell of the rise and fall of the Tibetan Plateau 3Snails tell of the rise and fall of the Tibetan Plateau 4Snails tell of the rise and fall of the Tibetan Plateau 5Snails tell of the rise and fall of the Tibetan Plateau 6Snails tell of the rise and fall of the Tibetan Plateau 7Fred Baxendale selected as Honorary Member of the Entomological Society of America 2
... , April 27 ARES Corporation ... operations division has been certified to the rigorous ... ISO 9001:2008 quality standard.  This certification signifies ARES, ... standards and strengthens our competitive position by standardizing ...
... , HOUSTON , April 27 Landry,s ... "Company") announced today that after lengthy negotiations with the Special ... the plaintiff in a lawsuit pending in Delaware , ... with the plaintiff,s attorneys to settle the stockholder derivative claim ...
... NEW YORK, April 27, 2010 The Juvenile Diabetes ... Living Cell Technologies (LCT), a New Zealand-based biotechnology company ... II clinical trial to study the safety and effectiveness ... treatment for type 1 diabetes with significant hypoglycemia unawareness. ...
Cached Biology News:ARES Aerospace and Defense Division Receives AS9100 Certification 2Landry's Restaurants, Inc. Announces Status of Acquisition by Tilman J. Fertitta and Tentative Partial Settlement of Delaware Lawsuit 2Landry's Restaurants, Inc. Announces Status of Acquisition by Tilman J. Fertitta and Tentative Partial Settlement of Delaware Lawsuit 3Landry's Restaurants, Inc. Announces Status of Acquisition by Tilman J. Fertitta and Tentative Partial Settlement of Delaware Lawsuit 4JDRF partners with LCT to test encapsulated cell replacement therapy for the treatment of diabetes 2JDRF partners with LCT to test encapsulated cell replacement therapy for the treatment of diabetes 3
... can perform many sophisticated DNA analysis and protein ... than just another sequence analysis product. Imagine having ... analyses to be performed each time you have ... sheets which specify exactly how your output will ...
... does for enzyme-/substrate-based blotting what intensifying screens do ... up to 10-fold (or one order of magnitude) ... Signal Enhancer membrane treatment is a simple, 15-minute ... current Western blotting protocol. The result is an ...
These stopping screens are for the biolistic PDS-1000 He and Hepta systems. Supplied as 500 screens....
...
Biology Products: